News

Nasdaq9mon
EYLEA HD® (aflibercept) Injection 8 mg Data at EURETINA Reinforce Long-term Durability, Sustained Fluid Control and Safety Profile
Injection 8 mg and EYLEA® (aflibercept) Injection 2 mg will be presented at the Annual Meeting of the European Society of Retina Specialists (EURETINA) in Barcelona from September 19 to 22 ...
Morningstar1mon
EYLEA HD® (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Continued Safety and Efficacy and Highlight Early Real-World Outcomes for Patients with Serious Retinal ...
EYLEA® (aflibercept) Injection 2 mg is a prescription medicine approved for the treatment of patients with Wet Age-Related Macular Degeneration (AMD), Macular Edema following Retinal Vein ...
Seeking Alpha1mon
EYLEA HD® (aflibercept) Injection 8 mg sBLA Accepted for FDA Priority Review for Both the Treatment of Macular Edema Following Retinal Vein Occlusion (RVO) and for Monthly ...
EYLEA ® (aflibercept) Injection 2 mg is a prescription medicine approved for the treatment of patients with Wet Age-Related Macular Degeneration (AMD), Macular Edema following Retinal Vein ...
Hosted on MSN16d
Bayer Gets CHMP Nod for Eylea 8 mg in the EU for 2 Major Eye Diseases
Eylea 8 mg continued to demonstrate a favorable safety profile in the third year, consistent with the well-established safety profile of Eylea 2 mg. Long-term safety data revealed no new safety ...
WCBD1mon
Regeneron Provides Update on EYLEA HD® (aflibercept) Injection 8 mg Supplemental Biologics License Application
EYLEA ® (aflibercept) Injection 2 mg is a prescription medicine approved for the treatment of patients with Wet Age-Related Macular Degeneration (AMD), Macular Edema following Retinal Vein ...